ライフサイエンスコーパス: mortality risk

1 rmed HLA DSA is associated with an increased mortality risk.

2 gree of optimism was associated with a lower mortality risk.

3 fection is associated with a sizeable excess mortality risk.

4 igence, higher allostatic load and increased mortality risk.

5 e effect of rapid privatisation on all-cause mortality risk.

6 , 2.61; 95% CI, 1.14-5.97) were at increased mortality risk.

7 h increased total and certain cause-specific mortality risk.

8 n among patients with low, moderate, or high mortality risk.

9 ent's functional status, muscle strength and mortality risk.

10 potato consumption is associated with higher mortality risk.

11 can help pinpoint patients with the highest mortality risk.

12 s appears to be associated with an increased mortality risk.

13 , remission, duration, severity, deaths, and mortality risk.

14 =35) was associated with a greater all-cause mortality risk.

15 lower all-cause mortality and 26% lower CVD mortality risk.

16 on score to more accurately reflect waitlist mortality risk.

17 reviously associated with cardiovascular and mortality risk.

18 partment populations with a wide spectrum of mortality risk.

19 he number of incident metabolic diseases and mortality risk.

20 or neuroticism as determinants of long-term mortality risk.

21 roupings that were independent predictors of mortality risk.

22 s that muscle composition is associated with mortality risk.

23 IgA anti-tTG were associated with increased mortality risk.

24 associated with a longer survival and lower mortality risk.

25 sis and potentially increasing the patient's mortality risk.

26 y associated with substantial differences in mortality risk.

27 rtional hazard models were used to determine mortality risk.

28 ng inflammatory processes that contribute to mortality risk.

29 deterioration and a substantially increased mortality risk.

30 can help pinpoint patients with the highest mortality risk.

31 can be used to stratify patients at varying mortality risk.

32 s critical in determining subsequent cardiac mortality risk.

33 tes a population with particularly increased mortality risk.

34 5% CI, 1.08 to 1.19) independently increased mortality risk.

35 ir association with antithrombotic drugs and mortality risk.

36 llowing diagnosis of CRC was associated with mortality risk.

37 to assess which traits determine a species' mortality risk.

38 d to mild mutations (p < 0.001), but similar mortality risk.

39 as associated with a significantly increased mortality risk.

40 evated IgA anti-tTG antibodies had increased mortality risk.

41 grip strength (GS) is associated with lower mortality risk.

42 rail recipients may be a marker of increased mortality risk.

43 nt groups and between those with the highest mortality risk.

44 ated the proportion of GBS disease in NE and mortality risk.

45 strongly related to poor prognosis and high mortality risk.

46 at denser clots are independently related to mortality risk.

47 for adaptation, and increasing morbidity and mortality risk.

48 pulations, frailty is associated with higher mortality risk.

49 e in heart rate is associated with increased mortality risk.

50 to assess the association of ethnicity with mortality risk.

51 trations have been associated with increased mortality risk.

52 g immune suppression and carries significant mortality risk.

53 nder, co-morbidities and confusion increased mortality risk.

54 er-generation fluoroquinolone might increase mortality risk.

55 ty are both independent predictors of higher mortality risk.

56 worship services is associated with a lower mortality risk.

57 associated with a substantial and comparable mortality risk.

58 ms and gymnosperms experienced roughly equal mortality risks.

59 ficantly lower all-cause and cancer-specific mortality risks.

60 led to demonstrate a significant decrease in mortality risk (0.72; .46-1.12).

61 that DFU-ISIs were associated with increased mortality risk (1.987; 1.106-3.568).

62 res was linked to 1.33 times the lung cancer mortality risk (95% confidence interval: 1.24, 1.40), as

63 rican American individuals have an increased mortality risk across multiple surgical procedures.

64 f the range of potential future heat-related mortality risks across the 21st century in New York City

65 m/s, patients with Vmax >/=5 m/s had greater mortality risk (adjusted hazard ratio=1.86 [1.55-2.54];

66 en early-life disease exposure and all-cause mortality risk after age 15 or 50.

67 iomarkers were significantly associated with mortality risk after controlling the false discovery rat

68 transplant anniversary, and nearly twice the mortality risk after year 3.

69 nts, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual

70 mortality, whereas the MHO group had a lower mortality risk (all-cause: 0.81 [0.74-0.88]), cardiovasc

71 s for both inpatient and early postdischarge mortality risk, allowing comprehensive risk assessment o

72 Mortality risk also declined when >4 clones coexisted in

73 hy imaging, and knee extension strength with mortality risk among 4,824 participants aged 76.4 (stand

74 We assessed hospital all-cause 30-day excess mortality risk among 8952 adults undergoing percutaneous

75 lty increases early hospital readmission and mortality risk among kidney transplantation (KT) recipie

76 We compared mortality risk among non-Hispanic black, Hispanic, and n

77 Mortality risk among patients admitted at weekends was h

78 e survival analysis revealed a higher 90-day mortality risk among T homozygotes than among C-allele c

79 substantially decrease the greatly elevated mortality risk among these patients.

80 ndexes have not been fully evaluated against mortality risk among U6M infants.The aim was to determin

81 tumour, we used data from the Apolipoprotein MOrtality RISk (AMORIS) (n = 528,580) and the Metabolic

82 idea using the specific factor of extrinsic mortality risk, an important factor in evolutionary theo

83 Here we aimed to study maternal mortality risk and causes, care-seeking patterns, and co

84 to elicit perceptions of changes in maternal mortality risk and health service provision, along with

85 later-generation fluoroquinolones may reduce mortality risk and improve treatment outcomes for drug-r

86 sociations of sex, race, and region with SLE mortality risk and revealed significant racial/ethnic di

87 mission within 30 days, with high associated mortality risks and costs.

88 <30; HR, 0.52; 95% CI, 0.35-0.77) had lower mortality risks, and patients who were class I obese (BM

89 mon, morbid, and costly; increases patients' mortality risk; and can be mitigated by limiting contras

90 e melanoma, NHL, and cerebrovascular disease mortality risks are possibly due to radiation.

91 2006 U.S. dollars) or $1 billion if reduced mortality risks are valued with willingness-to-pay or as

92 eduction revealed a network consisting of 18 mortality risk assessment genes related to tumor protein

93 om among the proteins directly related to 80 mortality risk assessment genes.

94 determined the frequency, risk factors, and mortality risk associated with DFU-ISIs.

95 The higher mortality risk associated with excess adiposity is atten

96 Few studies have examined the variation in mortality risk associated with heat during the summer.

97 All cities showed a substantial increase in mortality risk associated with mean daily temperature, w

98 This mortality risk associated with positive fluid balance, h

99 using a dynamic soil-plant-atmosphere model, mortality risks associated with hydraulic failure and st

100 Overall, mortality risk at 6 months was 61 per 100 person-years.

101 splantation (HTx) recipients experience high mortality risk attributed to increased nonadherence to i

102 arts, there was no significant difference in mortality risk between African American HHD and KTx pati

103 did not observe significant interaction for mortality risk between initiation time and baseline hear

104 Muscle composition may affect mortality risk, but prior studies have been limited to s

105 ving a deceased donor transplant reduced the mortality risk by 72% (hazard rate, 0.28 (0.20-0.39).

106 Among cancer survivors, mortality risk by CVD status was examined using Cox regr

107 both in terms of exposures to greenness and mortality risks, by personal socioeconomic status among

108 ate their children, and perceptions of local mortality risk can be so distorted as to constitute an i

109 injury (AKI), a common condition with a high mortality risk, can be facilitated by specific and relia

110 teristics, sepsis definitional elements, and mortality risk categories as covariates.

111 rends in sepsis definitional elements and in mortality risk categories based on organ dysfunction com

112 f follow-up, HHD patients had 4 times higher mortality risk compared with KTx recipients in the entir

113 presence of both AF and HF portended greater mortality risk compared with neither condition, particul

114 g northern latitude increases the additional mortality risk conferred by a diagnosis in winter (pinte

115 findings implied that increased disease and mortality risk could be transmittable via the transfer o

116 Mortality risk did not differ by group (70 per 100 perso

117 Estimates of mortality risk differed among exposure models.

118 This difference in mortality risk diminished after 2 years (hazard ratio, 1

119 lem that implicates inequities and extrinsic mortality risk - documenting more future-oriented thinki

120 suggest a 47% reduction in esophageal cancer mortality risk due to endoscopic screening, which may ha

121 ociation between strict BP control and lower mortality risk during two decades of follow-up of prior

122 Mortality risk escalated continuously with increasing nu

123 f cases, and is associated with an increased mortality risk, especially for VLST.

124 inical decision aid comparing individualized mortality risk estimates for dialysis versus transplanta

125 Children with HIV have an increased mortality risk, even when receiving tuberculosis treatme

126 Ambient PM2.5 was the fifth-ranking mortality risk factor in 2015.

127 age is a strong, continuous, and independent mortality risk factor in patients with BRAF V600E mutati

128 at diagnosis has been widely used as a major mortality risk factor in the risk stratification of papi

129 whether patient age at diagnosis is a major mortality risk factor.

130 In models adjusted for mortality risk factors (age, race/ethnicity, smoking, an

131 roportional hazards regression to adjust for mortality risk factors.

132 hosphatemia and hyperkalemia, which are also mortality risk factors.

133 rapies without considering objective patient mortality risk factors.

134 nt knowledge of ARDS trends in incidence and mortality, risk factors, and recently described endotype

135 Literature generally finds no advantages in mortality risk for albumin over cheaper alternatives in

136 There was similar mortality risk for black and white patients with OHCA in

137 was associated with approximately 2.7% lower mortality risk for both mothers (total ndeaths = 79,702)

138 The ratio of the non-AIDS-related mortality risk for current smokers versus that for never

139 weekend staffing of hospital specialists and mortality risk for emergency admissions.

140 At least half the excess mortality risk for individuals with CHC in the United St

141 The 22-year mortality risk for patients with severe hypertriglycerid

142 model, uses biomarkers to estimate baseline mortality risk for pediatric septic shock.

143 rtance of these disorders with regard to the mortality risk for persons with ASD.

144 The co-occurrence of ASD added no additional mortality risk for persons with neurologic (aHR, 0.7 [95

145 indicate tallness is associated with higher mortality risks for adults starting dialysis, but this a

146 d engineering categories had higher relative mortality risks for lung, gastric, and colorectal cancer

147 ) and 25% (95% CI: 16%, 33%) lower all-cause mortality risks for men and women, respectively, compare

148 and agriculture and forestry had the higher mortality risks for those cancers.

149 Attributable mortality risk (fraction of mortality that can be preven

150 R) function, which incorporated estimates of mortality risk from previous cohort studies in western E

151 n multivariable analysis, the cardiovascular mortality risk gradient across the 4 concordant or disco

152 ighest volume hospitals had higher predicted mortality risk, greater number of acutely dysfunctional

153 racteristics of DFU-ISIs and their effect on mortality risk have not been defined.

154 est) was associated with 19% lower all-cause mortality risk (hazard ratio (HR) = 0.81, 95% confidence

155 ar adipose tissue was associated with higher mortality risk (hazard ratio (HR) = 1.13 (95% confidence

156 minute was associated with a 20% increase in mortality risk (hazard ratio 1.20, 95% confidence interv

157 veloped CVD had an 11-fold increased overall mortality risk (hazard ratio, 10.9; 95% CI, 8.1 to 14.8)

158 cipients of elderly DCD kidneys had a 5-year mortality risk higher than that of elderly recipients of

159 ency was associated with considerably higher mortality risk (HR 2.14; 95% CI: 1.48, 3.08) than a suff

160 .72, 0.91; Ptrend = 0.006) and 28% lower CVD mortality risk (HR = 0.72, 95% CI: 0.60, 0.86; Ptrend =

161 pose tissue was associated with an 8% higher mortality risk (HR = 1.08, 95% CI: 1.01, 1.16).

162 tion was also associated with greater 5-year mortality risk (HR = 1.845; 95%CI [1.166-2.920], p = 0.0

163 , although the white HHD patients had higher mortality risk (HR, 4.21; 95% CI, 3.10-5.73; total event

164 There were no differences in nonrelapse mortality risks (HR, 0.92; P = .74) but relapse risks we

165 patients according to their 3-month waitlist mortality risk (i.e., concordance-statistic) was 0.80 an

166 n for coronary artery disease were at higher mortality risk in 10 of 12 models.

167 CPMs, women with heart failure were at lower mortality risk in 8 of 8 models; women undergoing revasc

168 entration with cardiovascular biomarkers and mortality risk in a large cohort of patients referred fo

169 toes) is associated with increased premature mortality risk in a North American cohort.A longitudinal

170 ECG parameters are independent predictors of mortality risk in a prospective cohort of participants w

171 a and IL6 levels were associated with higher mortality risk in both unadjusted and fully adjusted mod

172 Risk Model (PERSEVERE) to estimate baseline mortality risk in children with septic shock.

173 etes was not associated with adjusted 90-day mortality risk in critically ill patients admitted with

174 The role of extrinsic mortality risk in driving behaviour is probably importan

175 rd a higher proportion of UFAs may lower CVD mortality risk in drug-treated patients with cardiac dis

176 , higher BMI associated with lower all-cause mortality risk in inflamed patients (HR [95% CI] for Q1:

177 usted time-dependent analyses, the all-cause mortality risk in noninflamed patients was higher only i

178 uoroquinolones significantly reduced patient mortality risk in our cohort, suggesting that removal of

179 resenting to ETUs and conferred an increased mortality risk in patients infected with Ebola virus, su

180 and incrementally associated with increased mortality risk in patients with chronic heart failure.

181 is associated with a significantly increased mortality risk in patients with PD, after adjusting for

182 Conclusion The long-observed age-associated mortality risk in PTC is dependent on BRAF status; age i

183 chanisms by which PRA confers an incremental mortality risk in sensitized patients, and the role of t

184 To do so, we estimated 12-month mortality risk in simulated populations differing in pre

185 Male breast cancer incidence and mortality risk in the Japanese atomic bomb survivors - d

186 ained a significant covariate for the 90-day mortality risk in the multivariate analysis (hazard rati

187 was associated with significant decreases in mortality risk in the presence of a ASP, but not in its

188 rdiovascular diseases (CVDs) has the highest mortality risk in USA and Europe with 15-20 million case

189 T-allele was associated with higher CVD and mortality risk in women but not in men (P-sex interactio

190 Diabetes was associated with higher mortality risk, including overall (adjusted hazard ratio

191 significant reclassification of longer-term mortality risk (integrated discrimination index, 0.07 [0

192 The mortality risk is evaluated in response to both individu

193 The increase in mortality risk is expected to be higher for needleleaf f

194 es (T2D) than type 1 diabetes (T1D), but the mortality risk is higher in T1D than in T2D.

195 Investigators have examined whether heat mortality risk is increased in neighborhoods subject to

196 dards (NAAQS) every 5 years, but evidence of mortality risk is lacking at air pollution levels below

197 However, we suggest that mortality risk is not the primary mechanism leading to t

198 vel crystalline silica (silica) exposure and mortality risk is not well understood.

199 e had increased all-cause and cardiovascular mortality risks (log rank P=0.004 and P=0.003, respectiv

200 ation between attending worship services and mortality risk may be due to a number of different facto

201 We developed a TAVR in-hospital mortality risk model and used it to quantify variation i

202 ers, OCD was still associated with increased mortality risk (MRR, 1.88 [95% CI, 1.27-2.67]).

203 Ecological interactions that influence mortality risk, nutrient availability, and pathogen burd

204 ne to 6 months was associated with increased mortality risk of 23.8%, 32.9%, or 42.8%.

205 ounting to pound2 billion and average 30-day mortality risk of 7.5%.

206 al could substantially reduce disparities in mortality risk of non-Hispanic black children treated wi

207 We investigated cause-specific mortality, risk of subsequent primary neoplasms (SPNs),

208 e associated with significant differences in mortality risk on Kaplan-Meier analyses (P </= 0.002 for

209 ry modest to no increase in age-standardized mortality risk or ESRD.

210 , particularly CPTC, with a disease-specific mortality risk order of the genetic duet>>>>BRAF V600E a

211 , particularly CPTC, with a disease-specific mortality risk order of the genetic duet>>>>BRAF V600E a

212 nalysis suggests a reduction of heat-related mortality risk over the summer, which can be attributed

213 all-patient refined diagnosis-related group mortality risk (p < 0.001), and lower resource utilizati

214 tion was independently associated with lower mortality risk (P=0.001).

215 Annual mortality risk per thousand tons of precursor emissions

216 Factors included in the mortality risk prediction models for dialysis and transp

217 hemselves strong predictors) not did improve mortality risk prediction, the combination of brain-pred

218 Six-year lung cancer incidence and mortality risk predictions were assessed for (1) calibra

219 t TMAO quartile had a crude 1.86-fold higher mortality risk (Ptrend < 0.001).

220 associated with decreased risk of all-cause mortality (risk ratio = 0.74, 95% confidence intervals:

221 sociated with an increased risk of all-cause mortality (risk ratio [RR] 1.14 [95% CI 1.05-1.24] for s

222 associated with decreased risk of all-cause mortality (risk ratio [RR], 0.86 [95% CI, 0.80 to 0.93];

223 hermia were associated with 18% reduction in mortality (risk ratio, 0.82; 95% CI, 0.70-0.96; p = 0.01

224 that preventive antifungal did not decrease mortality (risk ratio, 0.88; 95% CI, 0.74-1.04; p = 0.14

225 DFT cohorts were found in terms of all-cause mortality (risk ratio, 0.90; 95% confidence interval, 0.

226 ts (risk ratio, 0.97; 95% CI, 0.65-1.43), or mortality (risk ratio, 0.93; 95% CI, 0.84-1.03; I2 = 0%)

227 hypothermic treatment with a 66% increase in mortality (risk ratio, 1.66; 95% CI, 1.06-2.59; p = 0.03

228 nstem lesions were associated with all-cause mortality (risk ratio, 1.78; 95% CI, 1.01-3.15; I = 43%)

229 s associated with a substantial reduction in mortality [risk ratio (RR) 0.63, 95% confidence interval

230 The minimally adjusted hazard ratio for mortality risk related to loneliness was 1.38 (95% CI 1.

231 the model as a time-dependent covariate, the mortality risk remained greater in carriers (HR = 1.65;

232 atients with MELD 15 or less where the early mortality risk remained significant.

233 Mortality risks remained elevated for CAS after adjustin

234 a reduced model performance and will deflate mortality risk, resulting in falsely high standardized m

235 This study aimed to develop a waitlist mortality risk score from commonly available candidate v

236 atients, as determined by ACTION in-hospital mortality risk score or initial troponin level.

237 on and age, can be included in an Aortopathy Mortality Risk Score to predict survival.

238 ICU utilization hospitals, the median ACTION mortality risk score was 33 for patients treated in the

239 The all-cause mortality risk score was calculated using 0.0398 x (age)

240 eloped simple heart failure (HF) in-hospital mortality risk scores.

241 This was similar to the excess mortality risk seen among the CAD control subjects compa

242 atures of macrophage activation syndrome for mortality risk stratification should be undertaken to co

243 bines protein and mRNA biomarkers to provide mortality risk stratification with possible clinical uti

244 ould perform as well for early postdischarge mortality risk stratification.

245 In the Apolipoprotein-related MOrtality RISk study, we enrolled 636,132 men and women

246 95% CI, 1.16-2.00), and an overall increased mortality risk (subdistribution HR, 2.10; 95% CI, 1.61-2

247 cute myocardial infarction (AMI) have higher mortality risk than similarly aged men.

248 herapy during the later interval had a lower mortality risk than those treated with surgery only (HR,

249 stantive in competing multivariate models of mortality risk than weight loss-based metrics (Bayesian

250 Calculate mortality risk that accounts for both severity and recov

251 ecurrence post ablation is associated with a mortality risk that is highest soon after the ablation a

252 oviral therapy treatment plans to the 5-year mortality risk that would had been observed under an int

253 ss-inducing high temperatures and associated mortality risk that would otherwise arise over 14 degree

254 T) and HIV suppression and may contribute to mortality risks that exceed those in HIV-uninfected popu

255 otatoes was not associated with an increased mortality risk.The frequent consumption of fried potatoe

256 ile, those in the middle tertile had similar mortality risk (TNF-alpha: HR, 1.09; 95% CI, 0.74-1.61;

257 time required for adjusted rehospitalization/mortality risks to decline 50% from maximum values after

258 se probability weights to compare the 5-year mortality risk under observed antiretroviral therapy tre

259 present data suggest that the morbidity and mortality risks vary substantially among these medicatio

260 of this common laboratory test in predicting mortality risk warrants further study.

261 The mortality risk was 2-fold higher through young adulthood

262 Mortality risk was evaluated using Cox regression model

263 In those with high baseline MSIS-29 scores, mortality risk was even greater if the MSIS-29 score wor

264 46% of mortality risk was explained by multivariable modelling

265 INTERPRETATION: Early mortality risk was extremely high among hospitalised HIV

266 was observed among Hispanics, in that lower mortality risk was found for all social integration cate

267 Excess mortality risk was found for concordant causes of death

268 PERSEVERE-based mortality risk was generated for each study subject (n =

269 Mortality risk was high with AVA/height <0.45 cm(2)/m (a

270 dictive value of CE fraction for three-month mortality risk was higher compared to INR (p = 0.04).

271 The mortality risk was higher in patients having isolated CA

272 Mortality risk was highest in patients diagnosed with bo

273 The 90-day mortality risk was recorded as the primary outcome param

274 No significant difference in mortality risk was recorded between accelerated infusion

275 s were transplanted with deceased donor, the mortality risk was reduced by 55% (hazard rate, 0.45 (0.

276 The mortality risk was significantly lower with mRDT than wi

277 Mortality risk was similar for Vmax 5 to 5.49 m/s and Vm

278 Although the 1-year mortality risk was slightly higher in the lead explantat

279 The mortality risk was slightly lower with mRDT in studies w

280 ssess the contribution of HRBs to the excess mortality risk, we determined the all-cause mortality ra

281 Dependent on the calculated mortality risk, we propose to stratify patients with acu

282 Patients in the lowest quartile of mortality risk were more likely to be screened than thos

283 Significant decreases in mortality risk were observed with both gram-positive (OR

284 All-cause mortality risk were raised with dental plaque, gingival

285 .1% for those who did, and the corresponding mortality risks were 55.7% and 89.9%, respectively.

286 The predicted prestage 1 and 2 mortality risks were calculated for each patient.

287 Materials and Methods Mortality risks were compared in nationwide cohorts of 4

288 All-cause mortality risks were generally lower for obese but stron

289 ; 95% confidence interval=0.76-1.03; P=0.10) mortality risks were similar in menthol compared with no

290 stricted cubic splines identified the lowest mortality risk when chemotherapy was started 50 days pos

291 Women with CAC scores >10 had a higher mortality risk when compared with men.

292 onfidence interval: 1.02, 2.60) elevation in mortality risk when cVL2 was accumulated from baseline.

293 r minute was associated with lower all-cause mortality risk: When compared with the first quartile, t

294 irst quartile chloride had a higher adjusted mortality risk, whether they had first quartile sodium (

295 was observed to be associated with increased mortality risk, which aligns with prior studies.

296 lower all-cause mortality and 16% lower CVD mortality risk with high yogurt intake.

297 ts, males and rural residents had higher TBI mortality risk, with adjusted mortality rate ratios of 2

298 lity, and strength was associated with lower mortality risk, with decreases ranging between 11% and 2

299 lity, and strength was associated with lower mortality risk, with decreases ranging between 12% and 1

300 RAAS inhibitor-induced WRF have an increased mortality risk, without experiencing improved outcome wi